<DOC>
	<DOC>NCT02510781</DOC>
	<brief_summary>Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive. The investigators witnessed a higher pathological complete remission(pCR) rate but no obvious increase in cardiac toxicity when used the anthracycline instead of carboplatin. The investigators expect to carry out a large sample size clinical research to optimize the existing therapeutic regimen</brief_summary>
	<brief_title>A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>18≤aged＜70 pathologic diagnosis of invasive breast cancer，staging ii to iii，the diameters≥2cm indicated by MRI or axillary lymph node（+） Immunohistochemical（IHC） positive for 3+ or FISH（+） clear hormone receptor（HR） status Eastern cooperative oncology group(ECOG)=0/1 LVEF≥55% pathologic grading of Miller and Payne screening laboratory values with the following parameters：absolute neutrophils acount：≥1500/mm3,total bilirubin:≤2.0×ULM,Aspartate transaminase (AST)/ALT≤2.5×ULM,platelet≥80000/mm3，serum creatinine≤1.5×ULM no pregnant or nursing signed Informed consent forms prior exposure to any treatments for breast cancer inflammatory/Bilateral/IV stage breast cancer poor physical condition pregnant or nursing Cardiac risk（Congestive heart failure、arrhythmia、myocardial infarct、Refractory hypertension（systolic pressure＞180mmHg/diastolic pressure＞100mmHg）） any other cancer within 5 years prior to screening with the exception of cervical carcinoma and non melanoma skin cancer Allergic to chemotherapy drugs</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>